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Background-—We aim to determine the prevalence of anemia in acute coronary syndrome (ACS) patients and compare their
clinical characteristics, management, and clinical outcomes to those without anemia in an unselected national ACS cohort.
Methods and Results-—The Myocardial Ischemia National Audit Project (MINAP) registry collects data on all adults admitted to
hospital trusts in England and Wales with diagnosis of an ACS. We conducted a retrospective cohort study by analyzing patients in
this registry between January 2006 and December 2010 and followed them up until August 2011. Multiple logistic regressions
were used to determine factors associated with anemia and the adjusted odds of 30-day mortality with 1 g/dL incremental
hemoglobin increase and the 30-day and 1-year mortality for anemic compared to nonanemic groups. Analyses were adjusted for
covariates. Our analysis of 422 855 patients with ACS showed that 27.7% of patients presenting with ACS are anemic and that
these patients are older, have a greater prevalence of renal disease, peripheral vascular disease, diabetes mellitus, and previous
acute myocardial infarction, and are less likely to receive evidence-based therapies shown to improve clinical outcomes. Finally,
our analysis suggests that anemia is independently associated with 30-day (OR 1.28, 95% CI 1.22-1.35) and 1-year mortality (OR
1.31, 95% CI 1.27-1.35), and we observed a reverse J-shaped relationship between hemoglobin levels and mortality outcomes.
Conclusions-—The prevalence of anemia in a contemporary national ACS cohort is clinically signiﬁcant. Patients with anemia are
older and multimorbid and less likely to receive evidence-based therapies shown to improve clinical outcomes, with the presence
of anemia independently associated with mortality outcomes. ( J Am Heart Assoc. 2016;5:e003348 doi: 10.1161/
JAHA.116.003348)
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B oth registry data
1-4 and secondary analyses of random-
ized controlled trials5-7 have suggested that the burden
of anemia in patients presenting with acute coronary
syndromes (ACS) is signiﬁcant. A recent meta-analysis of 27
studies including 233 144 patients has reported a prevalence
of anemia in ACS patients close to 20%,8 and current clinical
guidelines fail to offer ﬁrm recommendations for its concur-
rent management in the ACS setting.9,10
Patients with anemia are older3,6,7,11 with a signiﬁcantly
greater burden of comorbidities such as chronic kidney
disease,12-14 diabetes,6,13,14 heart failure,13,15 and more
extensive coronary artery disease6 and are less likely to
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undergo cardiac catheterization.4,6,11 These adverse clinical
characteristics are well known to contribute to adverse
outcomes in patients with ACS. Previous reports have
suggested that ACS patients with anemia have signiﬁcantly
worse in-hospital and longer-term total and cardiac mortality
outcomes,5-7,16,17 heart failure,18 and risk of major bleeding6
and of reinfarction.6,8,19 Some studies have reported that,
once differences in age or comorbidity burden between
anemic/nonanemic ACS cohorts are adjusted for, anemia is
no longer an independent predictor of adverse mortality20 or
cardiovascular mortality,21 although other studies report that
the relationship persists.6,7,19,22 Other studies have reported
different relationships between anemia and cardiovascular
(CV) outcomes according to sex, with baseline anemia
independently associated with higher rates of all-cause and
cardiac mortality at 30 days and 1 year in men but not in
women.7
Data derived from secondary analyses from randomized
controlled trials (RCT) have suggested adverse mortality
outcomes associated with anemia in patients with ACS,5,6,23
but such RCTs often exclude older patients with the most
severe comorbid conditions and may therefore underreport
the prevalence of anemia and underestimate its prognostic
impact. Many of the studies that have reported relationships
between anemia and adverse outcomes in the setting of ACS
have not adjusted for or excluded patients with major
bleeding events3,5,24 that may further confound the relation-
ships reported.
We have estimated the prevalence of anemia in ACS
patients and compared their clinical characteristics, manage-
ment, and clinical outcomes to those without anemia in an
unselected national ACS cohort derived from the Myocardial
Ischaemia National Audit Project (MINAP) registry, which
collects data on all patients in the UK admitted with a
conﬁrmed diagnosis of ACS. We also examined the relation-
ship between anemia and short- (30-day) and longer-term
(1-year) mortality outcomes in this setting and assessed
whether the prognostic impact of anemia relates to its severity.
Methods
Study Design and Population
The MINAP registry collects data on all patients aged 18 or
over in the United Kingdom who are admitted to all 230 NHS
hospital trusts in England and Wales with a conﬁrmed
diagnosis of an ACS. We analyzed data from the registry for
patients admitted between January 2006 and December 2010
on this registry and followed them up until August 2011.
Participants were included in the current study if they had a
diagnosis of any ACS (ST-segment elevation myocardial
infarction [STEMI], non–ST-segment elevation myocardial
infarction [NSTEMI], or unstable angina) determined by the
medical team at time of discharge. Mortality outcome was
ascertained by linkage through the Ofﬁce of National Statis-
tics.25
Data Collection
The MINAP data set collects standardized data on prehospital
and in-hospital care for all ACS admissions from all 230
NHS trusts in England and Wales and is part of the NHS
data dictionary (http://www.hqip.org.uk/minap-2013-report/).
The data are collected by nurses and clinical audit staff and
contain 123 ﬁelds. The details of development and initial
ﬁndings are reported elsewhere.26
In the current study variables included in the analyses were
hemoglobin at the time of admission with an ACS, age, sex,
smoking status, peak troponin levels, hyperlipidemia, hyper-
tension, prior angina, prior myocardial infarction, prior heart
failure, prior stroke, peripheral vascular disease, chronic
obstructive pulmonary disease, diabetes, renal failure, prior
percutaneous coronary intervention, prior coronary artery
bypass graft, prior medications (angiotensin-converting
enzyme [ACE] inhibitor, b-blocker, statin, clopidogrel, aspirin),
clinical diagnosis (unstable angina, NSTEMI, STEMI), discharge
medications (ACE inhibitor, b-blocker, statin, clopidogrel,
aspirin), angiography, in-hospital bleeding, and mortality
outcomes in hospital and within 30 days and 1 year. World
Health Organization (WHO) hemoglobin thresholds were used
to deﬁne anemia as <13 g/dL for men and <12 g/dL for
women.
Statistical Analysis
Multiple imputations by chained equations in STATA version
13.0 were used to impute missing values for variables where
possible. We describe baseline variables according to whether
they were missing or nonmissing in tables, and details of
participant inclusion are shown graphically. Descriptive
statistics are presented for baseline variables and outcome
according to anemia status and sex. Associations between
anemia status and individual variables were tested using
1-way analysis of variance for continuous variables and Chi-
squared test for categorical variables. We used multiple
logistic regression with adjustments for baseline variables to
determine factors associated with anemia. The same regres-
sion methods were used to determine the adjusted odds of
30-day mortality with 1 g/dL incremental hemoglobin
increase from <10 to ≥18 g/dL for men and from <9 to
≥17 g/dL for women. These results were presented graph-
ically. Additional analyses were performed to determine the
adjusted odds ratio of mortality at 30 days and 1 year for
anemic compared to nonanemic groups for the whole cohort,
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the male-only cohort, female-only cohort, NSTEMI cohort,
STEMI cohort, and subgroups where bleeding was excluded.
The baseline variables of the group of participants who bled
and did not bleed were also compared. Further analysis was
performed restricting the cohort that had no imputations.
Severity of anemia was examined by stratifying the cohort by
sex-speciﬁc hemoglobin cutoffs (Hb <10 g/dL, Hb 10-11 g/
dL, Hb 11-12 g/dL, Hb 12-13 g/dL, Hb ≥13 g/dL for men
and Hb <9 g/dL, Hb 9-10 g/dL, Hb 10-11 g/dL, Hb 11-12 g/
dL, Hb ≥12 g/dL for women). To better control for baseline
differences across the anemic and nonanemic groups, further
analysis was performed using propensity score matching (mi
estimate:teffects psmatch) to estimate average treatment
effects (ATE). Although multiple regression is the most widely
used method to control for measured confounders, it can be
inadequate when the 2 comparator groups (anemia vs no
anemia in our analyses) are very different across key
confounders. Propensity score matching can be a better
approach in such extreme scenarios and can thus serve as a
useful sensitivity analysis. Propensity scores were calculated
using multiple logistic regression, and then 1:1 matching with
replacement (ie, including all cases and controls) was
performed prior to simple logistic regression models to obtain
the ATE. Statistics to demonstrate the success of the
matching are also reported.
Ethical Considerations
The current study obtained the ethical approval from the
Faculty of Medicine & Health Sciences Research Ethics
Committee, University of East Anglia. Informed consent from
participants was waived as data were routinely collected, and
only anonymized data were used in the study.
Results
There were a total of 424 848 participants in the MINAP
cohort between January 2006 and December 2010 who were
followed up until August 2011. Of them, hemoglobin values
were recorded in 257 999 patients. Figure S1 shows the ﬂow
diagram of participant inclusion, and comparison of charac-
teristics between those with and without available data on Hb
did not show any material differences (Table S1).
The prevalence of anemia in this cohort was 71 223/
256 744 (27.7%). After multiple imputations the sample size of
the complete data set with all imputed variables was 256 744.
The descriptive statistics of baseline variables in the
included cohort, sorted by anemia status, are shown in
Table 1. The anemic cohort was signiﬁcantly older, with a
higher proportion of smokers (85% vs 68%, P<0.001), prior
hypertension (59% vs 48%, P<0.001), angina (43% vs 27%,
P<0.001), myocardial infarction (38% vs 23%, P<0.001), prior
heart failure (12% vs 4%, P<0.001), stroke (14% vs 7%,
P<0.001), peripheral vascular disease (8% vs 3%, P<0.001),
COPD (18% vs 14%, P<0.001), diabetes (31% vs 16%,
P<0.001), and renal failure (19% vs 4%, P<0.001). Participants
who were anemic were more likely to have aspirin and
clopidogrel prior to admission (7% vs 5%, P<0.001) and less
likely to be prescribed dual antiplatelet therapy on discharge
(75% vs 79%, P<0.001). Participants whose anemia occurred
in the context of a bleeding complication were more likely to
be female, to be on aspirin before admission and on discharge
(30% vs 28%, P<0.001), to have STEMI diagnosis (52% vs 38%,
P<0.001), to be less likely to receive angiography (26% vs
38%, P<0.001) and more likely to die at 30 days (6% versus
3%, P<0.001) and 1 year (12% vs 8%, P<0.001) (Table S2).
Similar rates of angiography were performed in the anemic
versus nonanemic cohort, but patients with anemia were
signiﬁcantly less likely to be prescribed secondary prevention
medications postdischarge. The difference in crude mortality
rates between the anemic and nonanemic groups increased
with longer follow-up.
Multiple logistic regression was used to determine the
independent factors associated with the presence of anemia
at baseline (Table 2). The most signiﬁcant associations were
observed with presence of peripheral vascular disease (OR
1.427, 95% CI 1.362-1.496, P<0.001), diabetes mellitus
(OR 1.786, 95% CI 1.742-1.832, P<0.001), and renal disease
(OR 3.058, 95% CI 2.962-3.158, P<0.001).
The adjusted odds of mortality by incremental (1 g/dL)
increase in hemoglobin are shown in Figure 1. Lower
hemoglobin values were associated with signiﬁcantly higher
mortality with a nonsigniﬁcant trend toward higher mortality
in those patients with elevated hemoglobin values.
The odds of mortality associated with the presence of
anemia following adjustment for baseline covariates are
shown in Table 3. We observed that there was a ~1.3-fold
increase in odds of 30-day mortality (OR 1.281, 95% CI 1.217-
1.350, P<0.001) and 1-year (OR 1.311, 95% CI 1.274-1.348,
P<0.001) mortality, respectively, with anemia after adjust-
ment for potential confounders. Similar signiﬁcant increases
in mortality with anemia were observed for men (30-day
mortality OR 1.298, 95% CI 1.217-1.384, P<0.001; 1-year
mortality OR 1.354, 95% CI 1.299-1.411, P<0.001) and
women (30-day mortality OR 1.255, 95% CI 1.146-1.374,
P<0.001; 1-year mortality OR 1.252, 95% CI 1.198-1.309,
P<0.001) as well as diagnosis of NSTEMI (30-day mortality OR
1.291, 95% CI 1.213-1.374, P<0.001; 1-year mortality OR
1.326, 95% CI 1.281-1.374, P<0.001) and STEMI (30-day
mortality OR 1.269, 95% CI 1.163-1.384, P<0.001; 1-year
mortality OR 1.284, 95% CI 1.284-1.352, P<0.001). In order
to eliminate the potential confounding inﬂuence of major
bleeding complications on the relationship between anemia
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Table 1. Baseline Characteristic of the MINAP Cohort According to Anemia Status
Variable*† No Anemia (n=185 521) Anemia (n=71 223) P Value†
Mean age, y 66 (14) 76 (12) <0.001
Male (%) 124 143/185 521 (67%) 44 027/71 223 (62%) <0.001
Current or ex-smokers 118 634/174 003 (68%) 54 361/64 210 (85%) <0.001
Peak troponin NA
Median troponin I (IQR), lg/L 1.1 (0.2-7.1) 1.0 (0.2-5.3)
Median troponin T (IQR), lg/L 1.2 (0.2-7.4) 1.0 (0.2-5.6)
Mean troponin I (SD), lg/L 10 (24) 9 (22)
Mean troponin T (SD), lg/L 10 (22) 8 (20)
Comorbidities
Hyperlipidemia 62 060/113 535 (35%) 24 442/67 499 (36%) <0.001
Hypertension 86 052/1 802 044 (48%) 40 573/69 230 (59%) <0.001
Prior angina 47 915/179 636 (27%) 29 629/68 890 (43%) <0.001
Prior myocardial infarction 41 215/180 166 (23%) 26 028/69 119 (38%) <0.001
Prior heart failure 7286/177 567 (4%) 7870/68 411 (12%) <0.001
Stroke 12 320/177 656 (7%) 9337/68 636 (14%) <0.001
PVD 5852/171 572 (3%) 5019/66 849 (8%) <0.001
COPD 24 625/173 811 (14%) 12 489/67 813 (18%) <0.001
Diabetes 29 016/180 989 (16%) 21 915/69 594 (31%) <0.001
Renal failure 7025/177 840 (4%) 13 283/68 831 (19%) <0.001
Prior PCI 18 865/179 306 (11%) 8354/68 560 (12%) <0.001
Prior CABG 10 522/179 580 (6%) 6858/68 799 (10%) <0.001
Medications prior to admission
ACE inhibitor 59 891/171 542 (35%) 31 984/66 325 (48%) <0.001
b-Blocker 49 387/171 865 (29%) 25 446/66 413 (38%) <0.001
Statin 71 339/173 840 (41%) 37 842/66 978 (57%) <0.001
Clopidogrel 13 506/81 575 (17%) 6782/29 402 (23%) <0.001
Aspirin 46 856/167 055 (28%) 18 593/64 237 (29%) <0.001
Aspirin and clopidogrel 3490/72 682 (5%) 1814/26 198 (7%) <0.001
Diagnosis at current admission <0.001
NSTEMI or unstable angina 104 928/170 135 (62%) 41 049/65 285 (63%)
STEMI 65 207/170 135 (38%) 24 235/65 285 (37%)
Medications at discharge
ACE inhibitor 121 885/185 521 (66%) 39 458/71 223 (55%) <0.001
b-Blocker 117 353/185 521 (63%) 38 709/71 223 (54%) <0.001
Statin 136 696/185 521 (74%) 47 976/71 223 (67%) <0.001
Clopidogrel 56 980/64 186 (89%) 17 381/20 595 (84%) <0.001
Aspirin 129 872/145 076 (90%) 49 657/55 517 (89%) 0.623
Aspirin and clopidogrel 39 445/50 208 (79%) 12 065/16 098 (75%) <0.001
Angiography performed
Angiography 70 914/185 521 (38%) 27 034/71 223 (38%) 0.319
Continued
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and mortality, we repeated the analysis following exclusion of
patients with major bleeding complications, and similar
results were recorded (30-day mortality OR 1.279, 95% CI
1.213-1.348, P<0.001; 1-year mortality OR 1.309, 95% CI
1.271-1.347, P<0.001). Furthermore, a sensitivity analysis
was undertaken in patients in whom Hb values were recorded
at baseline (257 999 patients), and similar independent
factors associated with anemia (Table S3) and mortality
outcomes associated with anemia (Table S4) were observed.
Propensity score matched analysis is shown in Table 4,
and anemia is associated with signiﬁcant increase in mortality
at both 30 days and 1 year after adjustments for propensity
score (30-day mortality coefﬁcient 0.0080, 95% CI 0.0045-
0.0114, P<0.001; 1-year mortality coefﬁcient 0.0173, 95% CI
0.0128-0.0218, P<0.001).
There were also differences in baseline characteristics
according to sex (Table 5). Most notably, females were
younger (mean age 74 vs 67 years, P<0.001), but more were
smokers (79% vs 70%, P<0.001) and hypertensive (56% vs
47%, P<0.001). However, medication at discharge was higher
in men, and women had a higher proportion of patients with
adverse outcomes.
The sex-speciﬁc adjusted odds of mortality by incremental
(1 g/dL) increase in hemoglobin is shown in Figure 2. For
both sexes, lower hemoglobin values were associated with
signiﬁcantly higher mortality, but high values of hemoglobin
were associated with higher mortality only in men and not in
women. Similar results were observed if patients with
bleeding were excluded (Figure S2).
In terms of severity of anemia there was an increase in
mortality at both 30 days and 1 year with reduced hemoglo-
bin, which ranged from ~1.2- to 1.3-fold increase in odds of
mortality for Hb 12 to 13 g/dL to a ~1.4- to 1.5-fold increase
for Hb <10 g/dL for men (Table 6). For women, similar
results were recorded.
Discussion
Our analysis is the largest analysis to study the prevalence,
clinical characteristics, and outcomes associated with anemia
in an unselected national cohort of ACS patients in the United
Kingdom. We have observed that more than 1 in 4 patients
presenting with ACS are anemic and that these patients are
older, have a greater prevalence of comorbid conditions, and
are less likely to receive evidence-based therapies shown to
improve clinical outcomes. Finally, our analysis suggests that
anemia is independently associated with adverse in-hospital
and longer-term mortality outcomes, with a reverse J-shaped
relationship between Hb levels and both short and longer
mortality outcomes observed.
Table 1. Continued
Variable*† No Anemia (n=185 521) Anemia (n=71 223) P Value†
Mortality outcomes
Mortality at 30 days 3425/184 228 (2%) 3691/70 771 (5%) <0.001
Mortality at 1 year 8520/183 041 (5%) 9173/70 339 (13%) <0.001
Bleeding outcomes
In-hospital bleeding 3475/174 183 (2%) 1337/67 023 (2%) 0.998
BMI indicates body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; MINAP, Myocardial Ischemia National Audit Project; NSTEMI, non–ST-
segment elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI, ST-segment elevation myocardial infarction.
*Results reported as mean (SD) for continuous variables and n (%) for categorical variables.
†Logistic regression (continuous variables), Chi-squared test (categorical variables).
Table 2. Signiﬁcant Factors Associated With Anemia
(n=422 855): Logistic Regression Model*
Variable Odds Ratio (95% CI) P Value
Age 1.046 (1.045-1.046) <0.001
Male sex 1.108 (1.088-1.128) <0.001
Smoker 1.243 (1.216-1.271) <0.001
Hypercholesterolemia 0.896 (0.876-0.916) <0.001
Angina 1.208 (1.182-1.235) <0.001
Previous myocardial
infarction
1.208 (1.182-1.235) <0.001
Previous heart failure 1.242 (1.192-1.293) <0.001
Previous stroke 1.191 (1.153-1.230) <0.001
PVD 1.427 (1.362-1.496) <0.001
COPD 1.109 (1.083-1.136) <0.001
Diabetes mellitus 1.786 (1.742-1.832) <0.001
Renal disease 3.058 (2.962-3.158) <0.001
Previous PCI 0.967 (0.935-1.000) 0.05
Previous CABG 1.074 (1.040-1.110) <0.001
Admission medication
Clopidogrel 1.223 (1.186-1.262) <0.001
Aspirin 1.024 (1.004-1.045) <0.001
CABG indicates coronary artery bypass graft; COPD, chronic obstructive pulmonary
disease; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease.
*All covariates in the table were included in the multiple logistic regression.
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Our observed prevalence of anemia of 28% is greater than
that reported in data derived from RCTs reporting rates of
between 10% and 25%,5-7,23 although registry data reveal
signiﬁcantly higher prevalences.4,12,27 For example, an anal-
ysis of 78 974 Medicare beneﬁciaries aged 65 years or older
hospitalized with acute myocardial infarction revealed a
prevalence of anemia of 43%.12 We have observed that ACS
patients with anemia are older, have a greater prevalence of
comorbid conditions, and are less likely to receive evidence-
based therapies for the treatment of ACS, in agreement with
previous literature.5-7,19,21
In the current analysis we report that the presence of
anemia is independently associated with an ~50% increased
risk of mortality in the short and long term and that this
prognostic impact is observed in both men and women, in
contrast to the ﬁndings of a secondary analysis of the
HORIZONS-AMI trial that failed to demonstrate an association
between anemia and increased risk of mortality in women.7
We have observed a reverse J-shaped relationship between
decreasing Hb values and 30-day mortality, with a dose-
response effect with progressively lower odds of survival with
more profound degrees of anemia in both men and women.
Similar reverse J-shaped relationships are seen between Hb
levels and CV death and the composite endpoint of CV death,
myocardial infarction, or recurrent ischemic events in some
studies,21 although other studies have not revealed such
statistically signiﬁcant relationships in either in-hospital
cardiac mortality16 or longer-term mortality.1
Previous studies have reported that anemia is independently
associated with adverse clinical outcomes, but many of these
studies did not report whether patients with bleeding events
were excluded from their analyses, as it is well documented
that major bleeding is independently associated with mortality
in the ACS setting,28-30 which might have confounded any
reported relationships between the presence of anemia and
mortality. In the current analysis we report anemia indepen-
dently predicts adverse mortality outcomes and that the J-
shaped relationship between Hb level and mortality persists
even after exclusion of patients with bleeding events.
There are several biological and clinical reasons why anemia
may lead to worse clinical outcomes in patients with ACS. In the
setting of ACS, anemia might worsen ischemia by decreasing
theoxygendelivery to the jeopardizedmyocardiumand increase
myocardial oxygen demand due to greater cardiac output to
maintain adequate systemic oxygen delivery.31,32 Clinically,
patients with anemia are often underprescribed antiplatelet
therapy due to bleeding concerns; for example, in our current
analysis clopidogrel was prescribed in 73% of patients without
anemia and 66% with anemia (P<0.001), whereas in the
CADILLAC trial 18% of patients with anemia at the time of their
ACS were no longer receiving aspirin at 1 year,23 which might
contribute to increased cardiovascular events. Analysis of the
Figure 1. Adjusted odds of mortality at 30 days according to hemoglobin levels for men and women.
Adjusted for age, sex, current or ex-smokers, troponin, hyperlipidemia, hypertension, prior angina, prior
myocardial infarction, prior heart failure, stroke, peripheral vascular disease, chronic obstructive pulmonary
disease, diabetes, renal failure, prior percutaneous coronary intervention, prior coronary artery bypass graft,
medications prior to admission, diagnosis, medications at discharge and angiography.
DOI: 10.1161/JAHA.116.003348 Journal of the American Heart Association 6
Anemia and Mortality in Acute Coronary Syndrome Mamas et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on N
ovem
ber 22, 2016
http://jaha.ahajournals.org/
D
ow
nloaded from
 
ACUITY trial suggests that patients with anemia were less likely
to undergo percutaneous coronary intervention (PCI) and more
likely to be medically managed, which may further contribute to
worse cardiovascular outcomes in this group.6 Finally, anemia
may be amanifestation of numerous chronic disease states, and
the presence of anemia is merely a marker of poorer outcomes
in patients with chronic diseases.
Our analysis suggests that anemia is independently associ-
ated with adverse clinical outcomes in patients presenting with
ACS. There is a lack of clarity in contemporary guideline
recommendations as to whether such patients with anemia
should be transfused and theoptimal transfusion strategy.33 The
American Association of Blood Banks recommendation for
patients presenting with ACS is “No recommendation for or
against a liberal or restrictive transfusion threshold for hospi-
talized, hemodynamically stable patients with acute coronary
syndrome.”33 Furthermore, the CRIT (conservative vs liberal red
cell transfusion in acute myocardial infarction) randomized pilot
trial34 demonstrated that patients with ACS and a hematocrit
level<30%whowere randomized to a liberal transfusion armhad
a signiﬁcantly higher composite endpoint of in-hospital death,
recurrent myocardial infarction, or congestive heart failure than
those who underwentmore restrictive transfusion practice (38%
vs 13%; P=0.046). In contrast, in the MINT (A Multicenter,
Randomized Study of Argatroban Versus Heparin as Adjunct to
Tissue Plasminogen Activator [TPA] in Acute Myocardial Infarc-
tion: Myocardial Infarction With Novastan and TPA) pilot study
undertaken in 110 patients presenting with an ACS or stable
anginawith anemia undergoing cardiac catheterization, patients
randomized to a liberal blood transfusion strategy had 50% lower
primary outcome rates of death, myocardial infarction, and
unscheduled revascularization compared to those patients
randomized to a restrictive transfusion strategy, with lower
30-day mortality too. A recent meta-analysis of 10 studies
consisting mainly of registry studies including 203 665 patients
has shown a close to 3-fold independent increase in the risk of
mortality associated with a liberal blood transfusion strategy in
the AMI setting with meta-regression adjusting for a history of
bleeding or baseline hemoglobin level revealing a similar
increased risk, indicating a signiﬁcant risk for blood transfusion
over and above that associated with bleeding or anemia,35 with
similar ﬁndings reported in the PCI setting.36
Table 3. Multivariate Association Between Anemia and
Mortality: Logistic Regression Models
Mortality Outcome N Odds Ratio (95% CI) P Value
Total cohort
Mortality at 30 days 420 614 1.281 (1.217-1.350) <0.001
Mortality at 1 year 418 471 1.311 (1.274-1.348) <0.001
Men only
Mortality at 30 days 274 278 1.298 (1.217-1.384) <0.001
Mortality at 1 year 272 812 1.354 (1.299-1.411) <0.001
Women only
Mortality at 30 days 146 336 1.255 (1.146-1.374) <0.001
Mortality at 1 year 145 659 1.252 (1.198-1.309) <0.001
NSTEMI
Mortality at 30 days 260 446 1.291 (1.213-1.374) <0.001
Mortality at 1 year 259 003 1.326 (1.281-1.374) <0.001
STEMI
Mortality at 30 days 159 962 1.269 (1.163-1.384) <0.001
Mortality at 1 year 159 265 1.284 (1.220-1.352) <0.001
Bleeding excluded
Mortality at 30 days 412 396 1.279 (1.213-1.348) <0.001
Mortality at 1 year 410 301 1.309 (1.271-1.347) <0.001
Men only
Mortality at 30 days 268 985 1.293 (1.209-1.381) <0.001
Mortality at 1 year 267 547 1.348 (1.294-1.405) <0.001
Women only
Mortality at 30 days 143 378 1.255 (1.150-1.371) <0.001
Mortality at 1 year 142 720 1.253 (1.198-1.310) <0.001
Total cohort without imputations
Mortality at 30 days
Unadjusted 254 999 2.905 (2.770-3.045) <0.001
Fully adjusted 34 861 1.472 (1.197-1.810) <0.001
Mortality at 1 year
Unadjusted 253 380 3.072 (2.978-3.168) <0.001
Fully adjusted 34 731 1.588 (1.430-1.763) <0.001
NSTEMI indicates non–ST-segment elevation myocardial infarction; STEMI, ST-segment
elevation myocardial infarction.
Table 4. Propensity Score Matching Analysis on 10 Imputed
Data Sets, Reporting Average Treatment Effects (ATE)
Analysis of Propensity Score Matching With ATE
Outcome N Coefﬁcient 95% CI P Value
30-day
mortality
121 979 0.0080 0.0045 to 0.0114 <0.001
1-year
mortality
121 276 0.0173 0.0128 to 0.0218 <0.001
Propensity Score Matching Statistics
Group Mean (SD) Median (IQR)
Case
(anemia)
0.739 (0.174) 0.782 (0.642, 0.875)
Control
(no anemia)
0.739 (0.174) 0.782 (0.642, 0.875)
Abs
(case-control)
0.00001 (0.00011) 79106 (29106, 0.00002)
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Table 5. Baseline Characteristic of the MINAP Cohort in a Single Imputed Data Set According to Sex
Variable*† Female (n=147 064) Male (n=275 791) P Value†
Mean age, y 74 (13) 67 (14) <0.001
Current or ex-smokers 103 049/131 067 (79%) 175 401/251 888 (70%) <0.001
Peak troponin NA
Median troponin I (IQR), lg/L 0.8 (0.2-4.4) 1.1 (0.2-7.0)
Median troponin T (IQR), lg/L 0.8 (0.1-5.6) 1.3 (0.2-9.4)
Mean troponin I (SD), lg/L 7 (20) 10 (23)
Mean troponin T (SD), lg/L 7 (18) 10 (22)
Comorbidities
Hyperlipidemia 45 444/132 621 (34%) 88 884/247 578 (36%) <0.001
Hypertension 77 462/137 388 (56%) 120 727/255 434 (47%) <0.001
Prior angina 45 397/136 047 (33%) 79 718/253 809 (31%) <0.001
Prior myocardial infarction 35 001/137 514 (25%) 72 795/256 934 (28%) <0.001
Prior heart failure 10 623/133 845 (8%) 13 559/248 960 (5%) <0.001
Stroke 13 854/133 862 (10%) 20 079/248 892 (8%) <0.001
PVD 5448/130 925 (4%) 12 219/243 539 (5%) <0.001
COPD 23 962/131 774 (18%) 34 462/244 671 (14%) <0.001
Diabetes 29 493/140 481 (21%) 51 424/262 468 (20%) <0.001
Renal failure 9795/134 079 (7%) 17 931/249 319 (7%) 0.196
Prior PCI 10 595/134 947 (8%) 30 254/251 990 (12%) <0.001
Prior CABG 5706/135 286 (4%) 20 933/252 728 (8%) <0.001
Medications prior to admission
ACE inhibitor 49 929/126 128 (40%) 88 256/234 196 (38%) <0.001
b-Blocker 41 213/126 289 (33%) 73 726/234 423 (31%) <0.001
Statin 58 420/129 601 (45%) 110 898/241 129 (46%) <0.001
Clopidogrel 15 230/77 245 (20%) 28 564/142 840 (20%) 0.115
Aspirin 37 535/131 780 (28%) 71 002/247 098 (29%) 0.103
Diagnosis at current admission 0.143
NSTEMI or unstable angina 83 404/134 524 (62%) 155 880/252 401 (62%)
STEMI 51 120/134 524 (38%) 96 521/252 401 (38%)
Medications at discharge
ACE inhibitor 83 277/147 064 (57%) 171 311/275 791 (62%) <0.001
b-Blocker 80 221/147 064 (55%) 165 753/275 791 (60%) <0.001
Statin 99 246/147 064 (67%) 196 756/275 791 (71%) <0.001
Clopidogrel 48 406/60 264 (80%) 98 181/115 628 (85%) <0.001
Aspirin 102 340/114 611 (89%) 192 059/215 135 (89%) 0.862
Angiography performed
Angiography 55 049/147 064 (37%) 103 267/275 791 (37%) 0.939
Mortality outcomes
Mortality at 30 days 5711/146 336 (4%) 7474/274 278 (3%) <0.001
Mortality at 1 year 14 149/145 659 (10%) 18 481/272 812 (7%) <0.001
In-hospital bleeding 2766/137 132 (2%) 4932/257 591 (2%) 0.027
BMI indicates body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; MINAP, Myocardial Ischemia National Audit Project; NSTEMI, non–ST-
segment elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STEMI, ST-segment elevation myocardial infarction.
*Results reported as mean (SD) for continuous variables and n (%) for categorical variables.
†Logistic regression (continuous variables), Chi-squared test (categorical variables).
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Our study has some limitations. TheMINAP data set requires
the recording of Hb within 24 hours of admission. Many of
these Hb values, particularly in the setting of hemodynamically
unstable NSTEMI or STEMI treated with primary PCI, may be
post-PCI and may reﬂect the inﬂuence of acute bleeding
complications and not reﬂect chronic anemia. Nevertheless,
Figure 2. Adjusted odds of mortality at 30 days according to hemoglobin levels and sex. Adjusted for
age, current or ex-smokers, troponin, hyperlipidemia, hypertension, prior angina, prior myocardial infarction,
prior heart failure, stroke, peripheral vascular disease, chronic obstructive pulmonary disease, diabetes,
renal failure, prior percutaneous coronary intervention, prior coronary artery bypass graft, medications prior
to admission, diagnosis, medications at discharge, and angiography.
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even following exclusion of patients who sustained bleeding
complications during their in-hospital course, the relationships
that we examined remained unchanged. We report an associ-
ation between anemia and in-hospital and longer-term mortal-
ity, but we cannot infer causality. Although it would be
interesting to know whether anemia was associated with
cardiac mortality, we were unable to determine the cause of
death for participants. We have adjusted for differences in
baseline characteristics between the anemic and nonanemic
cohorts, but other unmeasured confounders may be contribut-
ing to the adverse clinical outcomes associated with anemia
that we report. Another limitation was the missing data, which
varied in extent depending on the study variable, and we tried to
approximate these values using multiple imputations to impute
the missing values. Finally, the MINAP data set does not record
the receipt of blood transfusions, which may contribute to the
adverse clinical outcomes reported.35
Conclusions
In conclusion, this is the largest study of the prevalence,
clinical characteristics, and outcomes associated with anemia
in an unselected national cohort of ACS patients in the United
Kingdom. We report a signiﬁcant prevalence of anemia in a
contemporary ACS cohort, with approximately 1 in 4 patients
presenting with ACS being anemic, and that these patients
are older, have a greater prevalence of comorbid conditions,
and are less likely to receive evidence-based therapies shown
to improve clinical outcomes. Finally, our ﬁndings suggest
that anemia is independently associated with adverse 30-day
and longer-term mortality outcomes, with a reverse J-shaped
relationship between Hb levels and mortality outcomes
observed in both men and women. The clinical effectiveness
of correcting anemia routinely in ACS has not been widely
explored, and there is considerable uncertainty in the value of
such an approach. Targeted intervention strategies in this
patient population should be explored.
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Table 6. Evaluation of the Severity of Anemia by Sex Using Multiple Logistic Regression
Outcome
for Men Hemoglobin ≥13 Hemoglobin 12 to 13 Hemoglobin 11 to 12 Hemoglobin 10 to 11 Hemoglobin <10
Crude rate of
mortality at
30 days
5270/230 540 (2%) 666/18 252 (4%) 589/10 918 (5%) 458/7318 (6%) 491/7250 (7%)
Adjusted odds
of mortality
at 30 days
1.00 (reference) 1.21 (1.10-1.32),
P<0.001
1.35 (1.23-1.48), P<0.001 1.38 (1.23-1.54), P<0.001 1.38 (1.24-1.54), P<0.001
Crude rate of
mortality
at 1 year
12 967/229 347 (6%) 1703/18 135 (9%) 1440/10 844 (13%) 1129/7276 (16%) 1242/7210 (17%)
Adjusted odds
of mortality
at 1 year
1.00 (reference) 1.25 (1.18-1.33),
P<0.001
1.39 (1.31-1.48), P<0.001 1.42 (1.32-1.53), P<0.001 1.52 (1.42-1.63), P<0.001
Outcome for
Women Hemoglobin ≥12 Hemoglobin 11 to 12 Hemoglobin 10 to 11 Hemoglobin 9 to 10 Hemoglobin <9
Crude rate of
mortality at
30 days
4224/119 303 (4%) 550/12 595 (4%) 481/7882 (6%) 282/3869 (7%) 174/2687 (6%)
Adjusted odds
of mortality
at 30 days
1.00 (reference) 1.17 (1.05-1.30),
P=0.006
1.33 (1.19-1.48), P<0.001 1.38 (1.22-1.56), P<0.001 1.24 (1.04-1.47), P=0.015
Crude rate
of mortality
at 1 year
10 490/118 785 (9%) 1387/12 522 (11%) 1140/7842 (15%) 672/3839 (18%) 460/2671 (17%)
Adjusted odds
of mortality
at 1 year
1.00 (reference) 1.17 (1.11-1.24),
P<0.001
1.29 (1.20-1.38), P<0.001 1.37 (1.26-1.50), P<0.001 1.34 (1.20-1.50), P<0.001
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Table S1. Comparison of patients with missing and no missing hemoglobin values 
 
Variable†‡ No missing 
hemoglobin 
Missing hemoglobin 
Mean age (years) 69 (±14) 69 (±14) 
Male (%) 168,740/257,729 (65%) 107,805/166,421 (65%) 
Current or ex-smokers 173,966/239,409 (73%) 105,886/145,331 (73%) 
Peak troponin 
Median Troponin I (IQR) (µg/L) 
Median Troponin T (IQR) (µg/L) 
Mean Troponin I (SD) (µg/L) 
Mean Troponin T (SD) (µg/L) 
 
1.0 (0.2-6.5) 
1.1 (0.2-6.8) 
9.8 (±23.1) 
9.5 (±21.6) 
 
0.8 (0.1-4.6) 
0.8 (0.1-4.6) 
7.7 (±19.3) 
7.4 (±18.0) 
Comorbidities 
Hyperlipidemia 87,055/244,307 (36%) 48,030/137,680 (35%) 
Hypertension 127,321/250,699 (51%) 71,853/143,951 (50%) 
Prior angina 78,124/249,745 (31%) 47,790/141,926 (34%) 
Prior myocardial infarction 67,678/250,509 (27%) 40,725/145,773 (28%) 
Prior heart failure 15,263/247,189 (6%) 9,062/137,413 (7%) 
Stroke 21,784/247,508 (9%) 12,319/137,040 (9%) 
PVD 10,930/239,608 (5%) 6,821/136,614 (5%) 
COPD 37,359/242,828 (15%) 21,415/135,394 (16%) 
Renal failure 20,415/247,885 (8%) 7,453/137,312 (5%) 
Diabetes 51,220/251,808 (20%) 30,126/153,004 (20%) 
Prior PCI 27,391/249,078 (11%) 13,690/139,651 (10%) 
Prior CABG 17,520/249,593 (7%) 9,294/140,217 (7%) 
Medications prior to admission 
ACE inhibitor 92,430/239,043 (39%) 46,515/122,997 (38%) 
Beta blocker 75,333/239,462 (31%) 40,288/122,972 (33%) 
Statin 109,882/242,011 (45%) 60,424/130,487 (46%) 
Clopidogrel 20,493/111,931 (18%) 23,615/109,612 (22%) 
Aspirin 65,746/232,428 (28%) 43,268/148,246 (29%) 
Diagnosis at current admission 
NSTEMI or unstable angina 146,689 (62%) 93,749 (62%) 
STEMI 89,881 (38%) 58,441 (38%) 
Medications at discharge 
ACE inhibitor 162,012/257,999 (63%) 93,586/166,849 (56%) 
Beta blocker 156,807/257,999 (61%) 90,242/166,849 (54%) 
Statin 185,606/257,999 (72%) 111,758/166,849 (67%) 
Clopidogrel 74,777/85,595 (87%) 72,487/91,533 (79%) 
Aspirin 180,410/201,559 (90%) 115,392/129,727 (89%) 
Angiography performed 
Angiography 98,344/257,999 (38%) 60,770/166,849 (36%) 
Adverse outcomes   
Mortality at 30 days 7,147/256,244 (3%) 6,089/166,347 (4%) 
Mortality at 1 year 17,777/254,614 (7%) 15,004/165,816 (9%) 
In-hospital bleeding 4,833/242,369 (2%) 2,899/154,200 (2%) 
† Results reported as mean (SD) for continuous variables and n (%) for categorical variables. BMI=body mass 
index, COPD=chronic obstructive pulmonary disease, PVD=peripheral vascular disease, PCI=percutaneous 
coronary intervention, CABG=coronary artery bypass graft 
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Table S2. Baseline characteristic of the MINAP cohort according to bleeding status  
 
Variable†‡ No bleed (n=387,025) Bleed (n=7,698) p-value‡ 
Mean age (years) 69 (±14) 69 (±14) 0.49 
Male (%) 252,659/387,025 (65%) 4,932/7,698 (64%) 0.027 
Current or ex-smokers 255,007/350,600 (73%) 5,070/6,967 (73%) 0.95 
Peak troponin 
Median Troponin I (IQR) (µg/L) 
Median Troponin T (IQR) (µg/L) 
Mean Troponin I (SD) (µg/L) 
Mean Troponin T (SD) (µg/L) 
 
0.9 (0.2-5.7) 
1.0 (0.2-6.0) 
9 (±22) 
9 (±20) 
 
0.9 (0.2-6.2) 
1.1 (0.2-6.7) 
9 (±22) 
9 (±22) 
NA 
 
 
Comorbidities  
Hyperlipidemia 122,875/348,013 (35%) 2,521/6,929 (36%) 0.064 
Hypertension 181,448/359,503 (50%) 3,678/7,140 (52%) 0.082 
Prior angina 114,293/356,737 (32%) 2,261/7,111 (32%) 0.66 
Prior myocardial infarction 98,633/360,908 (27%) 1,930/7,172 (27%) 0.43 
Prior heart failure 22,106/350,347 (6%) 445/7,015 (6%) 0.91 
Stroke 31,051/350,336 (9%) 616/7,008 (9%) 0.83 
PVD 16,155/342,771 (5%) 327/6,849 (5%) 0.81 
COPD 53,567/344,689 (16%) 1,061/6,873 (15%) 0.82 
Diabetes 74,123/368,835 (20%) 1,479/7,326 (20%) 0.85 
Renal failure 25,446/350,922 (7%) 551/7,006 (8%) 0.050 
Prior PCI 37,473/354,160 (11%) 777/7,032 (11%) 0.21 
Prior CABG 24,400/355,121 (7%) 525/7,063 (7%) 0.065 
Medications prior to admission  
ACE inhibitor 126,548/329,866 (38%) 2,569/6,622 (39%) 0.48 
Beta blocker 105,134/330,237 (32%) 2,147/6,623 (32%) 0.32 
Statin 154,984/339,574 (46%) 3,123/6,813 (46%) 0.75 
Clopidogrel 39,264/198,190 (20%) 736/3,896 (19%) 0.11 
Aspirin 99,895/351,685 (28%) 2,166/7,166 (30%) 0.001 
Diagnosis at current admission <0.001 
NSTEMI or unstable angina 223,184/358,532 (62%) 3,536/7,302 (48%)  
STEMI 135,348/358,532 (38%) 3,766/7,302 (52%)  
Medications at discharge  
ACE inhibitor 223,296/387,025 (60%) 4,645/7,698 (60%) 0.91 
Beta blocker 225,456/387,025 (58%) 4,445/7,698 (58%) 0.37 
Statin 271,095/387,025 (70%) 5,405/7,698 (70%) 0.75 
Clopidogrel 132,016/158,384 (83%) 2,562/3,104 (83%) 0.23 
Aspirin 274,090/305,303 (90%) 4,230/5,631 (75%) <0.001 
Angiography performed  
Angiography 148,882/387,025 (38%) 2,039/7,698 (26%) <0.001 
Mortality outcomes    
Mortality at 30 days 11,711/384,955 (3%) 473/7,625 (6%) <0.001 
Mortality at 1 year 29,829/382,920 (8%) 889/7,578 (12%) <0.001 
† Results reported as mean (SD) for continuous variables and n (%) for categorical variables.  
‡ Logistic regression (continuous variables), Chi2 square test (categorical variables). 
BMI=body mass index, COPD=chronic obstructive pulmonary disease, PVD=peripheral 
vascular disease, PCI=percutaneous coronary intervention, CABG=coronary artery bypass 
graft 
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Table S3. Significant multivariate predictors of anemia in patients in whom baseline 
hemoglobin values were recorded (n=256,744) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable† Odds Ratio (95% CI) p-value ‡ 
Age 1.053 (1.052-1.054) <0.001 
Male sex 1.153 (1.129-1.176) <0.001 
Smoker 1.229 (1.196-1.263) <0.001 
Hypercholesterolemia 0.880 (0.861-0.991) <0.001 
Angina 1.048 (1.026-1.070) <0.001 
Previous myocardial infarction 1.214 (1.184-1.244) <0.001 
Previous heart failure 1.257 (1.211-1.304) <0.001 
Previous stroke 1.209 (1.171-1.247) <0.001 
Peripheral vascular disease 1.430 (1.367-1.496) <0.001 
Chronic obstructive pulmonary 
disease 
1.151 (1.121-1.181) <0.001 
Diabetes mellitus 1.942 (1.898-1.987) <0.001 
Renal disease 3.213 (3.107-3.323) <0.001 
Previous coronary artery bypass 
graft 
1.100 (1.060-1.141) <0.001 
Admission medication 
Clopidogrel 
Aspirin 
 
1.208 (1.159-1.259) 
1.029 (1.007-1.052) 
 
<0.001 
0.011 
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Table S4. Sensitivity analysis of multivariate association between anemia and mortality in 
patients in whom baseline hemoglobin values were recorded 
 
Total cohort 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 254,999 1.530 (1.452-1.612) <0.001 
Mortality at 1 year 253,380 1.589 (1.535-1.645) <0.001 
Men only 
Mortality at 30 days 166,996 1.566 (1.458-1.681) <0.001 
Mortality at 1 year 165,901 1.698 (1.620-1.780) <0.001 
Women only 
Mortality at 30 days 88,003 1.479 (1.369-1.599) <0.001 
Mortality at 1 year 87,479 1.459 (1.38501.536) <0.001 
 
Bleeding excluded 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 249,901 1.524 (1.445-1.608) <0.001 
Mortality at 1 year 248,317 1.584 (1.529-1.641) <0.001 
Men only 
Mortality at 30 days 163,723 1.553 (1.444-1.671) <0.001 
Mortality at 1 year 162,648 1.684 (1.605-1.766) <0.001 
Women only 
Mortality at 30 days 86,170 1.481 (1.368-1.603) <0.001 
Mortality at 1 year 85,660 1.464 (1.389-1.542) <0.001 
  
Total cohort without imputations 
Mortality outcome N Odds ratio (95% CI) p-value 
Mortality at 30 days 
Unadjusted  
Fully adjusted 
 
254,999 
34,861 
 
2.905 (2.770-3.045) 
1.472 (1.197-1.810) 
 
<0.001 
<0.001 
Mortality at 1 year 
Unadjusted  
Fully adjusted 
 
253,380 
34,731 
 
3.072 (2.978-3.168) 
1.588 (1.430-1.763) 
 
<0.001 
<0.001 
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Figure S1. Flow chart of patient inclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total sample size 424,848 of MINAP cohort.  
 257,999 participants with hemoglobin 
 422,591 participants with mortality at 30 days 
 420,430 participants with mortality at 1 year 
 
 
Total sample size 422,855 for each imputed dataset 
after imputations for all variables. 
Total sample size in anemia and relation to outcomes 
were: 
 412,396 participants for mortality at 30 days 
 410,301 participants with mortality at 1 year 
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Figure S2. Adjusted odds of mortality at 30 days according to hemoglobin levels and sex 
with exclusion of participants with bleed outcome 
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